This study aimed to characterize the 24-month risk of cervical intraepithelial neoplasia grade ... of endocervical CIN 1 contributes to additional risk of high-grade CIN compared with women ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive ...

A large majority of high-grade lesions in the female genital ... the vaccine was 100% effective in preventing cervical intraepithelial neoplasia (CIN)1-3 and adenocarcinoma in situ (AIS ...

which is used for primary screening and co-testing and can detect cervical intraepithelial neoplasia of grade 2/3 or worse. Roche's cobas HPV testing system was validated in the IMPACT trial ...

1 The New Technologies in Cervical Cancer ... The primary outcome was cervical intraepithelial neoplasia grade 2 (CIN2) or more severe lesions with a higher grade (CIN2 ...

The investigators assessed the efficacy of the vaccine against cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions ... or a control vaccine at 0, 1 and 6 months; of these women, 92% ...